Tirzepatide, with its dual GIP/GLP-1 action, may offer even stronger glycemic benefits, though this remains to be confirmed in a postpartum-specific population
The mechanism is sound and the early data is strong
At 40 weeks, all tirzepatide doses were superior to placebo in reducing HbA1c, fasting serum glucose, and bodyweight, with more participants on tirzepatide meeting HbA1c targets
We're not just interested in "normal" lab values
Pharmaceutical grade implies GMP manufacturing and extensive regulatory oversight, which dramatically increases production costs
Compounded versions from licensed 503A pharmacies provide additional cost and dosing flexibility, allowing providers to titrate doses more gradually if needed to minimize gastrointestinal side effects